The present invention corresponds to the field of cancer treatment and is related to compounds and compositions for their use in the treatment of cancer, in particular to inhibitors of platelet derived-endothelial cell growth factor (PD-ECGF) for their use in the treatment of cancer resistant to anti-angiogenic therapy.